CDC42 and nasopharyngeal carcinoma: It also affects nasopharyngeal carcinoma (NPC) progression, with downregulation linked to poor prognosis and inhibition of growth and invasion via FOXQ1 repression and Cdc42 pathway targeting (Cui and Zhao, 2019).